; (2) intravenous administration of a substance in schedule II, III, IV, or V under section 202 of the Controlled Substances Act that has not been approved for intravenous use under— (A) section 505 of the Federal Food, Drug and Cosmetic Act; or (B) section 351 of the Public Health Service Act; or (3) intravenous administration of a substance in schedule II, III, IV, or V under section 202 of the Controlled Substances Act that has not been prescribed to the person using the substance. (d) Authorization of appropriations For the purpose of carrying out this section, there are authorized to be appropriated $40,000,000 for each of the fiscal years 2019 through 2023. .